NEW YORK, Oct. 8 - Celera Genomics has bought from Bayer all rights to preclinical research held under an existing collaboration between the two companies. In the process, Celera has untied a research partnership in place since before the Applera unit bought Axys Pharmaceuticals last year.
Celera has acquired rights to all compounds, study data, and relevant IP related to the use of the compounds in all fields, including the primary area of application, which in this case are potential asthma therapies.
Financial details were not disclosed.
"We plan to obtain pilot scale quantities of these compounds and to complete additional IND-enabling toxicology and safety evaluations in the coming months," Robert Booth, Celera's senior vice president of research and development, said in a statement this morning.
The companies agreed to terminate the collaborative research-and-license agreement penned in November 1994 by Arris Pharmaceutical, a predecessor of Axys Pharmaceuticals, a company Celera bought in November 2001. The company operates as Celera South San Francisco.